Your evidence map for Crohn's disease and ulcerative colitis
Stem cell therapy for inflammatory bowel disease in Istanbul, Turkey
A clear guide from our Istanbul team separating diagnoses, severity, standard treat-to-target care, and where local fistula cell research actually applies.
Condition-specific editorial anatomy. Explanatory labels remain in accessible text.
Direct answer
What the current evidence says
There's no universal stem cell treatment for inflammatory bowel disease, and we don't pretend otherwise. Crohn's disease and ulcerative colitis differ in anatomy, complications, and evidence. The best developed MSC research concerned local treatment of selected complex perianal Crohn's fistulas — not routine intravenous treatment of luminal disease or ulcerative colitis. Request your free medical evaluation and we'll route you to the guide and care plan that fits your exact diagnosis.
Clinical map
Start with the diagnosis, stage, and treatment context
This page is a clinical map. Your dedicated Crohn's or fistula evaluation gets its own route-specific plan.
Established care comes first
- Risk-stratified therapy: We help select advanced therapy according to your diagnosis, severity, prior exposure, and preference.
- Objective monitoring: We use treat-to-target reassessment rather than relying only on how you feel day to day.
- Surgery when indicated: Surgery is never treated as a failure when it addresses uncontrolled colitis, obstruction, abscess, or fistula.
- 01
Crohn's disease
Can affect any gastrointestinal segment and may be inflammatory, stricturing, penetrating, or perianal.
- 02
Ulcerative colitis
Continuous colonic mucosal inflammation has its own severity, surveillance, and treatment pathway.
- 03
IBD complications
Bleeding, obstruction, abscess, and malnutrition can change urgency and are triaged first.
Evidence position
What is known, what is investigational, and what is not demonstrated
Diagnosis and phenotype set the plan
We measure objective inflammation with endoscopy, calprotectin, CRP, and imaging — not symptoms alone.
One label hides multiple diseases
Modern IBD care includes biologics, small molecules, nutrition, and timely surgery, all coordinated through your program.
Systemic infusion is not local fistula therapy
Results vary between patients and stem cell therapy is not a guaranteed cure — no generic MSC or exosome infusion has proven durable healing across IBD.
Product and route
A mechanism is not a clinical outcome
- 01
One label hides multiple diseases
Any plan we propose names Crohn's or ulcerative colitis, current activity, complications, and the exact target and endpoint.
BoundaryEvidence applies only to the studied product, population, dose, route, comparator, and endpoint.
- 02
Systemic infusion is not local fistula therapy
A local surgically coordinated protocol provides no proof for an IV cord-cell or exosome package, and we won't sell it as one.
BoundaryEvidence applies only to the studied product, population, dose, route, comparator, and endpoint.
Evidence ledger
Read the actual study, including the result that did not change
Each row keeps product identity, route, endpoint, and limitation together so one trial cannot become a generic treatment claim.
01 Advanced therapies in ulcerative colitis guideline
Open source- Product
- Approved biologics and small molecules, with no routine MSC recommendation
- Route
- Diagnosis-specific standard routes
- Design
- Evidence-based living guideline evaluating randomized clinical outcomes
- Finding
- Guideline recommendations focus on established advanced therapies and objective disease control.
- Limitation
- Absence from a guideline is not proof of impossibility, but it confirms cell infusion is not established IBD care.
02 Alofisel confirmatory experience
Open source- Product
- Expanded allogeneic adipose-derived MSCs
- Route
- Local perifistular injection after surgical preparation
- Design
- Product-specific phase 3 program for complex perianal Crohn's fistulas
- Finding
- The confirmatory trial did not show superiority to placebo and the product was withdrawn from the EU market.
- Limitation
- The evidence does not transfer to ulcerative colitis, luminal Crohn's disease, IV MSCs, or exosomes.
Outcomes before travel
Decide what meaningful change would look like
A baseline and a time point matter more than an isolated testimonial. These measures should be chosen before any intervention.
- 01
Endoscopic and histologic activity
- 02
Calprotectin, CRP, hemoglobin, and nutrition
- 03
Steroid-free clinical remission
- 04
Hospitalization, surgery, fistula, and infection
- 05
Quality of life and daily participation
Specialist review
What a complete Istanbul review needs
A clear guide from our Istanbul team separating diagnoses, severity, standard treat-to-target care, and where local fistula cell research actually applies.
Records and baseline
- Confirmed Crohn's disease or ulcerative colitis diagnosis
- Current disease extent, behavior, severity, endoscopy, and imaging
- Calprotectin, CRP, blood counts, and nutrition status
- Prior and current medicines, surgery, and response
- The product, target, route, and coordination plan with your home IBD team
Safety and planning checks
- Severe bleeding, obstruction, abscess, or dehydration always gets urgent conventional care first.
- We keep your effective medicines active unless your treating IBD specialist directs a change.
- Your Istanbul plan clearly separates experimental research from the standard options available for your exact diagnosis and severity.
Transparent planning
Build the medical plan before the package
A quote should follow record review, product disclosure, route rationale, and a written follow-up plan. This page does not invent a universal price.
- Severe bleeding, obstruction, abscess, or dehydration always gets urgent conventional care first.
- We keep your effective medicines active unless your treating IBD specialist directs a change.
- Your Istanbul plan clearly separates experimental research from the standard options available for your exact diagnosis and severity.
Questions the plan must answer
- 01
One label hides multiple diseases: Any plan we propose names Crohn's or ulcerative colitis, current activity, complications, and the exact target and endpoint.
- 02
Systemic infusion is not local fistula therapy: A local surgically coordinated protocol provides no proof for an IV cord-cell or exosome package, and we won't sell it as one.
Primary reading
Guidelines, trials, and regulatory context
FAQ
Questions patients ask before an Istanbul review
Request Medical Evaluation
Begin a personalized treatment conversation with our medical team.
Share your case in confidence. Our international coordinators review every enquiry and respond within 24 hours, in your language.